Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of$152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target to approximately$585 million Conference call to be held today, Monday, November 3, 2025, at 8:30 AM ET NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2025, along ...